Fusion antibodies for HIV therapy
US8637024B2 · kind B2 · utility
8Cited by
3References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 11, 2011 |
| Grant date | Jan 28, 2014 |
| Priority date | — |
| Expiry date | Nov 11, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.